The women's Canyon Slam team has suspended Shari Bossuit after she tested positive for the banned drug letrozole.

Letrozole is used primarily to treat estrogen-sensitive cancers in postmenopausal women. It is on WADA's banned list because its doping effects are similar to taking testosterone.

Belgian rider Toon Arts tested positive for the drug in late 2022. He denied any wrongdoing and refused to serve a two-year suspension, but could not prove that his case was due to drug contamination.

Bossuite and her manager will hold a press conference in Belgium on Monday morning to explain her case.

Because letrozole is considered a "specified substance" that does not require a mandatory provisional suspension, Bossuit was able to race as her case became clearer. She ran on the Paris-Roubaix Fam and the Canadian Nations Cup track in late April.

Bossuite and her manager informed Canyon-Scrum that both her A and B samples tested positive for letrozole from the French Anti-Dopage Agency (AFLD), which conducted testing at the March 19 Tour de Normandie Féminine A final decision was awaited.

Canyon-Slam extended her contract on April 5, but it now has a "tentative non-active" status.

"Canyon/Slam Racing takes a zero-tolerance stance on the use of prohibited substances in accordance with WADA anti-doping rules. Therefore, compliance with anti-doping rules is part of all agreements between all riders and CANYON/SRAM Racing," the team said in a statement released early Sunday morning.

"In accordance with the team's own anti-doping rules, the team has provisionally placed Shari on suspension from CANYON/SRAM Racing. The team is currently awaiting the AFLD's decision.

"We have a clear zero-tolerance stance against doping in sport. We have been in contact with Shari and her manager and are awaiting the AFLD's decision," said team manager Ronnie Lauke.